The U.S. Food and Drug Administration approves Revolution Medicines’ Rasonque (daraxonrasib), a once-daily targeted oral treatment for advanced pancreatic cancer. Multiple outlets report the approval follows clinical trial results showing improved outcomes versus standard chemotherapy.
Rasonque is designed to block several forms of the RAS protein, which is involved in tumor growth in many pancreatic cancers. Quartz and other coverage describe the drug’s benefit in a large trial, reporting that median overall survival nearly doubles compared with standard chemotherapy. Fox News adds that the treatment is positioned for patients whose cancer progresses after chemotherapy, while France 24 emphasizes its use in metastatic disease.
Outlets differ mainly in emphasis: some highlight the biological target and its relevance to pancreatic adenocarcinoma, while others focus on the survival improvement and the context of treatment after prior options. All agree the FDA action creates Revolution Medicines’ first approved therapy and provides a new option for people with advanced disease.
